Pictet Private Equity Investors S.A.

Type

Other

Status

Active

Location

Geneve, Switzerland

Total investments

22

Average round size

106M

Portfolio companies

20

Rounds per year

0.10

Lead investments

1

Follow on index

0.09

Exits

4

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyInternetSoftwareFinancial ServicesFinTechFinanceArtificial IntelligenceHealth CareMedicalPharmaceutical

Summary

In 1805 was created Pictet Private Equity Investors S.A., which is appeared as Corporate Investor. The company was established in Europe in Switzerland. The main office of represented Corporate Investor is situated in the Geneva.

Besides them, we counted 5 critical employees of this fund in our database.

The usual things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2000. The higher amount of exits for fund were in 2018. When the investment is from Pictet Private Equity Investors S.A. the average startup value is more than 1 billion dollars. Opposing the other organizations, this Pictet Private Equity Investors S.A. works on 9 percentage points more the average amount of lead investments.

The standard case for the fund is to invest in rounds with 7 partakers. Despite the Pictet Private Equity Investors S.A., startups are often financed by Bay City Capital, Versant Ventures, Venrock. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Venrock, VantagePoint Capital Partners. In the next rounds fund is usually obtained by Reference Capital SA, BZ Bank, 500 Startups.

Among the most successful fund investment fields, there are Biopharma, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, Albert, Bluetrain.com. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States.

Show more

Investor highlights

Stage focus
Seed

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
22
Lead investments
1
Exits
4
Rounds per year
0.10
Follow on index
0.09
Investments by industry
  • Biotechnology (9)
  • Pharmaceutical (6)
  • Medical (5)
  • Health Care (4)
  • Software (4)
  • Show 43 more
Investments by region
  • United States (11)
  • India (1)
  • Switzerland (5)
  • France (2)
  • United Kingdom (1)
  • Show 2 more
Peak activity year
2022
Number of Unicorns
4
Number of Decacorns
4
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Avg. valuation at time of investment
828M
Group Appearance index
1.00
Avg. company exit year
13
Avg. multiplicator
0.09
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Harbinger Health 28 Sep 2023 Biotechnology, Health Care, Health Diagnostics Early Stage Venture 140M United States, Massachusetts, Cambridge

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.